Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a substantial proportion of adults worldwide. Although research has established important roles for the bacterial gut microbiome, the intestinal virome—including bacteriophages and eukaryotic viruses—has received less attention. Human studies have reported associations between intestinal viral diversity or selected phage taxa and the severity of steatotic liver disease, while separate studies have described fungal-community changes in patients with fatty liver disease. These observations are not equivalent: the available MASLD-specific virome evidence remains limited, predominantly cross-sectional, and insufficient to establish whether viral changes precede disease, contribute causally, or follow bacterial and host metabolic alterations. Evidence from COVID-19 and Clostridioides difficile infection provides useful comparative context, but cannot establish a shared causal mechanism with MASLD. We therefore distinguish direct human MASLD observations from mechanistic evidence derived from other liver diseases, infections, animal models, or in vitro systems. We propose a testable framework in which phage–bacterium interactions may modify microbial ecology and host immune signaling, while emphasizing that direct virome-specific effects on hepatic immunometabolism and cross-organ communication remain largely unproven. Methodological heterogeneity and limited longitudinal data currently constrain translation into clinical practice.
No takes yet. Share an insight, caveat, or question.
Amr A. Hamed (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: